UK government’s drug policy advisory points out that ecstasy causes slight memory difficulties and mild depression, but they rarely translate into problems in the real world.
The UK Advisory Council on the Misuse of Drugs (ACMD) came to this conclusion after undertaking the biggest ever review to determine whether ecstasy damages health in the long term.
The review suggests that smaller studies do show that some individuals have problems like weakened immunity and larger memory deficits, but for most people ecstasy seems to be nowhere near as harmful over time as one may have been led to believe.
The committee may soon recommend downgrading ecstasy from a class A drug to a class B, putting it on a par with cannabis in terms of harmfulness.
The ACMD based their review largely on a study they commissioned from Gabriel Rogers and Ruth Garside of the Peninsula Medical School in Exeter, UK. They pulled together all the research from around the world that attempted to assess the health of people who had taken ecstasy, and reanalyzed the data from the 110 studies that dealt with long-term effects.
The committee found that compared with non-users, people who took even a small amount of ecstasy at some point consistently performed worse on psychometric tests, which measure mental performance, especially memory, attention and executive function, which includes decision-making and planning.
The most pronounced effects are on memory, mainly verbal and working memory.